Fraxin | CAS#524-30-1

MedKoo Cat#: 525139 | Name: Fraxin

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Fraxin is a glucoside of fraxetin, an O-methylated coumarin. Fraxin was administered orally to rats to investigate its metabolism.

Chemical Structure

Fraxin

CAS#524-30-1

Theoretical Analysis

MedKoo Cat#: 525139

Name: Fraxin

CAS#: 524-30-1

Chemical Formula: C16H18O10

Exact Mass: 370.0900

Molecular Weight: 370.31

Elemental Analysis: C, 51.89; H, 4.90; O, 43.21

Price and Availability

Size	Price	Availability	Quantity
100mg	USD 450.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Fraxin; Fraxine; Fraxetin-8-O-glucoside; Fraxetol 8-glucoside; Fraxoside

IUPAC/Chemical Name

2H-1-Benzopyran-2-one, 8-(beta-D-glucopyranosyloxy)-7-hydroxy-6-methoxy-

InChi Key

CRSFLLTWRCYNNX-QBNNUVSCSA-N

InChi Code

InChI=1S/C16H18O10/c1-23-7-4-6-2-3-9(18)25-14(6)15(11(7)20)26-16-13(22)12(21)10(19)8(5-17)24-16/h2-4,8,10,12-13,16-17,19-22H,5H2,1H3/t8-,10-,12+,13-,16+/m1/s1

SMILES Code

COC1=C(O)C(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)=C3C(C=CC(O3)=O)=C1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Fraxin shows its antioxidative effect through inhibition of cyclo AMP phosphodiesterase enzyme.

In vitro activity:

The results of the in vitro study conducted in HepG2 cells indicated that the CCl4-induced changes were significantly ameliorated by pretreatment of fraxin. Moreover, immunohistochemistry staining and western blot assay demonstrated that pretreatment with fraxin can down-regulate CCl4-induced protein expression of MAPKs, NF-κB and COX-2. Overall, these studies indicate that fraxin exhibits hepatoprotective effect against CCl4-induced liver damage by reducing inflammation response, suppressing oxidative stress and lipid peroxidation and enhancing antioxidant activity. Reference: Biomed Pharmacother. 2017 Nov;95:1091-1102. https://pubmed.ncbi.nlm.nih.gov/28922728/

In vivo activity:

32 Sprague Dawley male rats were divided into 4 groups. The groups were organized as follows; sham, IR, IR + fraxin 10 mg/kg, and IR + 50 mg/kg fraxin groups. It was detected that the oxidant and proinflammatory markers increased and antioxidant parameters decreased in IR group but the results significantly reversed in treatment groups compared to IR group. Reference: Life Sci. 2020 Feb 1;242:117217. https://pubmed.ncbi.nlm.nih.gov/31884094/

	Solvent	mg/mL	mM
Solubility
	DMSO	124.7	336.66
	DMF	50.0	135.02
	PBS (pH 7.2)	2.0	5.40

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 370.31 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Niu X, Liu F, Li W, Zhi W, Yao Q, Zhao J, Yang G, Wang X, Qin L, He Z. Hepatoprotective effect of fraxin against carbon tetrachloride-induced hepatotoxicity in vitro and in vivo through regulating hepatic antioxidant, inflammation response and the MAPK-NF-κB signaling pathway. Biomed Pharmacother. 2017 Nov;95:1091-1102. doi: 10.1016/j.biopha.2017.09.029. Epub 2017 Sep 14. PMID: 28922728. 2. Chang BY, Jung YS, Yoon CS, Oh JS, Hong JH, Kim YC, Kim SY. Fraxin Prevents Chemically Induced Hepatotoxicity by Reducing Oxidative Stress. Molecules. 2017 Apr 6;22(4):587. doi: 10.3390/molecules22040587. PMID: 28383514; PMCID: PMC6154468. 3. Topdağı Ö, Tanyeli A, Akdemir FNE, Eraslan E, Güler MC, Çomaklı S. Preventive effects of fraxin on ischemia/reperfusion-induced acute kidney injury in rats. Life Sci. 2020 Feb 1;242:117217. doi: 10.1016/j.lfs.2019.117217. Epub 2019 Dec 26. PMID: 31884094. 4. Li W, Li W, Yu J, Liu F, Zang L, Xiao X, Zhao J, Yao Q, Niu X. Fraxin inhibits lipopolysaccharide-induced inflammatory cytokines and protects against endotoxic shock in mice. Fundam Clin Pharmacol. 2020 Feb;34(1):91-101. doi: 10.1111/fcp.12500. Epub 2019 Aug 28. PMID: 31325387.

In vitro protocol:

In vivo protocol:

1. Topdağı Ö, Tanyeli A, Akdemir FNE, Eraslan E, Güler MC, Çomaklı S. Preventive effects of fraxin on ischemia/reperfusion-induced acute kidney injury in rats. Life Sci. 2020 Feb 1;242:117217. doi: 10.1016/j.lfs.2019.117217. Epub 2019 Dec 26. PMID: 31884094. 2. Li W, Li W, Yu J, Liu F, Zang L, Xiao X, Zhao J, Yao Q, Niu X. Fraxin inhibits lipopolysaccharide-induced inflammatory cytokines and protects against endotoxic shock in mice. Fundam Clin Pharmacol. 2020 Feb;34(1):91-101. doi: 10.1111/fcp.12500. Epub 2019 Aug 28. PMID: 31325387.

1: Yasuda T, Fukui M, Nakazawa T, Hoshikawa A, Ohsawa K. Metabolic fate of fraxin administered orally to rats. J Nat Prod. 2006 May;69(5):755-7. PubMed PMID: 16724835.